[{"id":"2a09abe0-6495-491d-a75a-5fe8da47ac10","acronym":"","url":"https://clinicaltrials.gov/study/NCT04086485","created_at":"2021-01-18T20:00:12.098Z","updated_at":"2025-02-25T12:27:19.621Z","phase":"Phase 1/2","brief_title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","source_id_and_acronym":"NCT04086485","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["BRCA • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-24"},{"id":"2a6d7e4f-c35c-4e6b-8dc6-72106bb36c61","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750954","created_at":"2023-12-06T16:15:46.614Z","updated_at":"2025-02-25T13:53:37.832Z","phase":"Phase 1","brief_title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04750954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-20"},{"id":"fdfd9de7-291d-41f6-a1e7-37009f68c58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665739","created_at":"2021-01-19T20:43:36.156Z","updated_at":"2025-02-25T14:15:45.821Z","phase":"Phase 2","brief_title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","source_id_and_acronym":"NCT04665739","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"dc4d04a6-0615-4ba1-8e7e-f73bd8437cb0","acronym":"CAAA603B12101","url":"https://clinicaltrials.gov/study/NCT05870579","created_at":"2023-05-23T16:06:09.074Z","updated_at":"2025-02-25T14:42:04.037Z","phase":"Phase 1","brief_title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","source_id_and_acronym":"NCT05870579 - CAAA603B12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • fulvestrant • goserelin acetate • AAA603"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2023","start_date":" 11/13/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 01/26/2032","study_completion_date":" 01/26/2032","last_update_posted":"2025-02-14"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"4be67477-813c-4d4a-afcc-f5d5c110e3d8","acronym":"ReLUTH","url":"https://clinicaltrials.gov/study/NCT04954820","created_at":"2021-07-08T14:52:46.401Z","updated_at":"2025-02-25T16:45:28.459Z","phase":"Phase 2","brief_title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","source_id_and_acronym":"NCT04954820 - ReLUTH","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/01/2031","primary_completion_date":" 10/01/2031","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2025-02-06"},{"id":"05512785-f9fe-439d-9e0c-f165bade4b72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206060","created_at":"2021-01-18T15:48:09.116Z","updated_at":"2025-02-25T16:44:08.576Z","phase":"Phase 2","brief_title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","source_id_and_acronym":"NCT03206060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • VHL • SSTR","pipe":" | ","alterations":" RET mutation • VHL mutation","tags":["NF1 • VHL • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-05"},{"id":"449ed9d2-cfb9-4804-ab05-1adc2070268b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122610","created_at":"2023-11-08T22:13:11.239Z","updated_at":"2025-02-25T16:47:11.811Z","phase":"Phase 1","brief_title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","source_id_and_acronym":"NCT06122610","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-05"},{"id":"11c83591-4e3f-4858-aa5c-0d9de1fd1c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691465","created_at":"2023-01-20T16:00:13.319Z","updated_at":"2025-02-25T16:54:41.696Z","phase":"Phase 2","brief_title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","source_id_and_acronym":"NCT05691465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • RB1 • SYP • CHGA","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-04"},{"id":"77bffc42-2b22-4b22-8139-b83130b4cbfe","acronym":"COMPOSE","url":"https://clinicaltrials.gov/study/NCT04919226","created_at":"2021-06-10T01:52:29.850Z","updated_at":"2025-02-25T17:37:09.573Z","phase":"Phase 3","brief_title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","source_id_and_acronym":"NCT04919226 - COMPOSE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-01-29"},{"id":"791ed3e1-159a-4669-b6a9-9650c77c7e2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079698","created_at":"2021-10-15T14:53:06.706Z","updated_at":"2025-02-25T15:54:10.535Z","phase":"Phase 1","brief_title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","source_id_and_acronym":"NCT05079698","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-03"},{"id":"5b3663eb-53d2-4913-aef6-1eb4ef0d39c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084338","created_at":"2023-10-16T15:12:50.854Z","updated_at":"2025-02-25T17:39:27.404Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc","source_id_and_acronym":"NCT06084338","lead_sponsor":"VA Office of Research and Development","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 11/29/2027","primary_completion_date":" 11/29/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-12-30"},{"id":"08d03f09-1c0e-4f63-9272-84ef1303882d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04529044","created_at":"2021-01-18T21:41:11.607Z","updated_at":"2025-02-25T15:44:08.465Z","phase":"Phase 2","brief_title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","source_id_and_acronym":"NCT04529044","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1 • CDK4 • SSTR","pipe":"","alterations":" ","tags":["PD-L1 • CDK4 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-12-20"},{"id":"8247cdb4-7bc6-434e-8424-d805cacb6db9","acronym":"LuCAB","url":"https://clinicaltrials.gov/study/NCT05340374","created_at":"2022-04-22T14:53:47.311Z","updated_at":"2025-02-25T17:37:46.899Z","phase":"Phase 1/2","brief_title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05340374 - LuCAB","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 06/20/2026","primary_completion_date":" 06/20/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-11-08"},{"id":"037190b9-a29c-4950-8488-50ec828ead4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609592","created_at":"2021-02-11T16:55:29.685Z","updated_at":"2025-02-25T15:44:13.594Z","phase":"Phase 1","brief_title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","source_id_and_acronym":"NCT04609592","lead_sponsor":"Stanford University","biomarkers":" SSTR","pipe":" | ","alterations":" PGR expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-10-28"},{"id":"0661b272-42c1-4893-b062-503b09cba715","acronym":"NELMAS","url":"https://clinicaltrials.gov/study/NCT05987176","created_at":"2023-08-14T15:10:04.790Z","updated_at":"2025-02-25T15:54:51.896Z","phase":"Phase 2","brief_title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","source_id_and_acronym":"NCT05987176 - NELMAS","lead_sponsor":"Imperial College London","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 08/02/2024","start_date":" 08/02/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 03/30/2029","study_completion_date":" 03/30/2029","last_update_posted":"2024-08-09"},{"id":"dcbd3293-1182-4c12-8316-c5f16bc55d47","acronym":"STRATUM","url":"https://clinicaltrials.gov/study/NCT05377034","created_at":"2023-01-30T19:59:50.852Z","updated_at":"2024-07-02T16:35:13.314Z","phase":"Phase 2","brief_title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","source_id_and_acronym":"NCT05377034 - STRATUM","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 04/26/2025","primary_completion_date":" 04/26/2025","study_txt":" Completion: 10/26/2026","study_completion_date":" 10/26/2026","last_update_posted":"2024-03-22"},{"id":"8e9016c5-f335-427f-9f26-0ca96ab2e497","acronym":"LANTana","url":"https://clinicaltrials.gov/study/NCT05178693","created_at":"2022-01-05T12:53:41.791Z","updated_at":"2025-02-25T15:54:18.184Z","phase":"Phase 1","brief_title":"Lutathera and ASTX727 in Neuroendocrine Tumours","source_id_and_acronym":"NCT05178693 - LANTana","lead_sponsor":"Imperial College London","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"98d02899-95e2-4460-970e-d8cfe1ea3235","acronym":"","url":"https://clinicaltrials.gov/study/NCT05315687","created_at":"2022-04-07T13:56:31.508Z","updated_at":"2024-07-02T16:35:22.912Z","phase":"Phase 2","brief_title":"Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy","source_id_and_acronym":"NCT05315687","lead_sponsor":"Emory University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-19"},{"id":"e15bb21d-5fb8-4e9d-8347-60a7b3d548d7","acronym":"TheraSphere","url":"https://clinicaltrials.gov/study/NCT00906984","created_at":"2021-01-18T03:30:04.724Z","updated_at":"2024-07-02T16:35:24.192Z","phase":"","brief_title":"TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT00906984 - TheraSphere","lead_sponsor":"University of California, Irvine","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraSphere (yttrium 90 microspheres)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-01-08"},{"id":"26d46d69-11f8-4786-88dd-d7c97f75f519","acronym":"","url":"https://clinicaltrials.gov/study/NCT02195011","created_at":"2021-01-18T10:15:51.950Z","updated_at":"2024-07-02T16:35:27.168Z","phase":"Phase 2","brief_title":"Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases","source_id_and_acronym":"NCT02195011","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 06/04/2017","primary_completion_date":" 06/04/2017","study_txt":" Completion: 06/04/2017","study_completion_date":" 06/04/2017","last_update_posted":"2023-12-05"},{"id":"d35bf2f8-c72c-4e41-b03f-2a4b88237830","acronym":"LuPARP","url":"https://clinicaltrials.gov/study/NCT04375267","created_at":"2021-01-18T21:08:12.416Z","updated_at":"2025-02-25T15:43:58.882Z","phase":"Phase 1","brief_title":"177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours","source_id_and_acronym":"NCT04375267 - LuPARP","lead_sponsor":"Vastra Gotaland Region","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-11-14"},{"id":"8f341beb-ea98-4529-9ae4-ee4c9f81d66b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01176604","created_at":"2021-01-18T04:41:50.199Z","updated_at":"2024-07-02T16:36:02.427Z","phase":"","brief_title":"Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT01176604","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraSphere (yttrium 90 microspheres)"],"overall_status":"Completed","enrollment":" Enrollment 299","initiation":"Initiation: 08/04/2010","start_date":" 08/04/2010","primary_txt":" Primary completion: 04/09/2021","primary_completion_date":" 04/09/2021","study_txt":" Completion: 04/09/2021","study_completion_date":" 04/09/2021","last_update_posted":"2022-10-14"},{"id":"e27f1808-0b58-4858-8e0b-e3c933950bde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02072356","created_at":"2021-01-18T09:32:53.284Z","updated_at":"2024-07-02T16:36:03.182Z","phase":"Phase 1","brief_title":"Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery","source_id_and_acronym":"NCT02072356","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraSphere (yttrium 90 microspheres)"],"overall_status":"Completed","enrollment":" Enrollment 290","initiation":"Initiation: 10/11/2010","start_date":" 10/11/2010","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2022-09-30"}]